170 related articles for article (PubMed ID: 18205559)
21. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
George B; Harris A; Mitchell A
Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
[TBL] [Abstract][Full Text] [Related]
22. PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example.
Whyte K
N Z Med J; 2005 Nov; 118(1226):U1759. PubMed ID: 16311607
[TBL] [Abstract][Full Text] [Related]
23. Provision of pharmaceuticals in Australian hospitals: equity of access?
Gallego G; Taylor SJ; Brien JA
Pharm World Sci; 2007 Apr; 29(2):47-50. PubMed ID: 17149650
[TBL] [Abstract][Full Text] [Related]
24. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
25. NICE and new drugs for rheumatoid arthritis.
Lancet; 2008 May; 371(9623):1477. PubMed ID: 18456081
[No Abstract] [Full Text] [Related]
26. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
Kim H; Byrnes J; Goodall S;
Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
[TBL] [Abstract][Full Text] [Related]
27. Relationship between financial impact and coverage of drugs in Australia.
Mauskopf J; Chirila C; Masaquel C; Boye KS; Bowman L; Birt J; Grainger D
Int J Technol Assess Health Care; 2013 Jan; 29(1):92-100. PubMed ID: 23217275
[TBL] [Abstract][Full Text] [Related]
28. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
Meron D
Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
[No Abstract] [Full Text] [Related]
29. Health economics and health technology assessment: perspectives from Australia and New Zealand.
Streat S; Munn S
Crit Care Clin; 2012 Jan; 28(1):125-33, vii. PubMed ID: 22123104
[TBL] [Abstract][Full Text] [Related]
30. Value-based pricing of drugs in the UK.
Webb DJ; Walker A
Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
[No Abstract] [Full Text] [Related]
31. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
32. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
33. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?
Tordoff JM; Norris PT; Reith DM
Value Health; 2005; 8(3):201-8. PubMed ID: 15877592
[TBL] [Abstract][Full Text] [Related]
34. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
35. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
Beatty PA; Laking GR
J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
[No Abstract] [Full Text] [Related]
36. Changes to the Pharmaceutical Benefits Advisory Committee.
Henry DA; Birkett DJ
Med J Aust; 2001 Mar; 174(5):209-10. PubMed ID: 11280687
[No Abstract] [Full Text] [Related]
37. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
38. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
39. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
40. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
